I agree that NWBO is in an interesting position because there is the ovarian cancer trial, the Direct Phase 1 trial, the dendritic cell is a dendritic cell mantra and multiple preclinical trials and other clinical trials as well as compassionate use of L outside of GBM that all validate the safe use of DC therapy in multiple tumor types. Your background is in manufacturing so you know that if there was no big picture involved the likelihood that we would have had an approval by now if planning an extended period of artisan method manufacturing would have come first. I think this is a big picture moment that regulators and others are still trying to wrap their heads around. Best wishes.
Market Data 
Markets 
AI
